UEG Podcast

Sphincter-preserving surgery spares most rectal cancer patients a stoma, but hands many of them low anterior resection syndrome (LARS). Three European surgeons join Harald Rosen in discussing follow-up, where transanal irrigation lands, when to involve the gastroenterologist, and where sacral neuromodulation fits.

EoE requires long-term management, but what does that look like in practice? In Part 2, Prof. Alex Straumann discusses the realities of treating a chronic, relapsing disease, where remission is achievable but a cure is not.

The episode explores how to approach maintenance therapy, manage persistent symptoms despite histological remission, and when to escalate treatment to biologics. It also addresses the practical limitations of dietary strategies and the ongoing challenge of identifying trigger foods.

Looking ahead, the discussion highlights key unmet needs in EoE, including the absence of reliable diagnostic tools for food triggers and the potential influence of modern food production on disease prevalence.

Part 2 will be released on Wednesday, the 29th of April.

Eosinophilic oesophagitis (EoE) is now a well-recognised condition. But it was not always so. In this episode, Prof. Alex Straumann shares how EoE was first identified, taking us back to the late 1980s when unusual cases of food impaction and eosinophilic inflammation did not fit any known diagnosis.

He discusses the clinical observations that led to recognising EoE as a distinct disease, the early case series that defined its phenotype, and the initial treatment approaches that shaped current practice. The episode also addresses key diagnostic challenges that remain relevant today, including the distinction from oesophageal eosinophilia and the limitations of symptom-based assessment.

In this episode, Pradeep Mundre speaks with Hannah Gordon about one of the most challenging areas in inflammatory bowel disease management: balancing effective treatment with cancer risk. As therapeutic options expand, clinicians increasingly face complex scenarios involving patients with prior malignancy in remission or those undergoing active cancer treatment. The discussion examines how cancer risk relates both to IBD itself and to immunosuppressive or biologic therapies. The episode highlights limitations in current evidence, differences across drug classes, and the importance of individualised decision-making. Emphasis is placed on multidisciplinary collaboration, patient communication, and navigating uncertainty in real-world clinical practice.

Cristian Costas, a leading dietitian in coeliac disease, shares insights on managing celiac disease through diet, setting up specialised services, and navigating dietary challenges. We explore diagnosis, implementation of a gluten-free diet, and strategies to improve patient outcomes.